Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 13 de 13
Chinese Journal of Gastrointestinal Surgery ; (12): 385-388, 2023.
Article in Chinese | WPRIM | ID: wpr-986803


With the increasing number of obese patients worldwide, metabolic and bariatric surgery (MBS) has quickly become an effective way to treat obesity and related metabolic diseases such as type 2 diabetes, hypertension, lipid abnormalities, etc. Although MBS has become an important part of general surgery, there is still controversy regarding the indications for MBS. In 1991, the National Institutes of Health (NIH) issued a statement on the surgical treatment of severe obesity and other related issues, which continues to be the standard for insurance companies, health care systems, and hospital selection of patients. The standard no longer reflects the best practice data and lacks relevance to today's modern surgeries and patient populations. After 31 years, in October 2022, the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), the world's leading authorities on weight loss and metabolic surgery, jointly released new guidelines for MBS indications, based on increasing awareness of obesity and its comorbidities and the accumulation of evidence of obesity metabolic diseases. In a series of recommendations, the eligibility of patients for bariatric surgery has been expanded. Specific key updates include the following: (1) MBS is recommended for individuals with BMI≥35 kg/m2, regardless of the presence, absence, or severity of co-morbidities; (2) MBS should be considered for individuals with metabolic diseases and BMI 30.0-34.9 kg/m2; (3) the BMI threshold should be adjusted for the Asian population:: BMI≥25 kg/m2 suggest clinical obesity, and BMI ≥ 27.5 kg/m2 population should consider MBS; (4) Appropriately selected children and adolescents should be considered for MBS.

Adolescent , Child , Humans , Diabetes Mellitus, Type 2/surgery , Bariatric Surgery , Obesity/surgery , Obesity, Morbid/surgery , Weight Loss
Chinese Journal of Gastrointestinal Surgery ; (12): 454-461, 2022.
Article in Chinese | WPRIM | ID: wpr-936102


Objective: To investigate the safety and learning curve of Da Vinci robotic single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) in the treatment of obesity patients. Methods: A descriptive case series study was performed. Clinical data of obesity patients who were treated with Da Vinci robotic SADI-S in China-Japan Union Hospital of Jilin University from March 2020 to May 2021 were analyzed retrospectively. Case inclusion criteria: (1) uncomplicated obese patients with body mass index (BMI)≥37.5 kg/m(2); (2) patients with BMI of 28 to <37.5 kg/m(2) complicated with type 2 diabetes or two metabolic syndrome components, or obesity comorbidities; (3) patients undergoing SADI-S by Da Vinci robotic surgery system. Those who received other bariatric procedures other than SADI-S or underwent Da Vince robotic SADI-S as revisional operation were excluded. A total of 77 patients were enrolled in the study, including 31 males and 46 females, with median age of 33 (18-59) years, preoperative body weight of (123.0±26.2) kg, BMI of (42.2±7.1) kg/m(2) and waistline of (127.6±16.3) cm. According to the order of operation date, the patients were numbered as 1-77. The textbook outcome (TO) and Clavien-Dindo grading standard were used to analyze the clinical outcome of each patient and to classify surgical complications, respectively. The standard of textbook outcome was as follows: the operative time less than or equal to the 75th percentile of the patient's operation time (210 min); the postoperative hospital stay less than or equal to the 75th percentile of the patient's postoperative hospital stay (7 d); complication grade lower than Clavien grade II; no readmission; no conversion to laparotomy or death. The patient undergoing robotic SADI-S was considered to meet the TO standard when meeting the above 5 criteria. The TO rate was calculated by cumulative sum analysis (CUSUM) method. The curve was drawn by case number as X-axis and CUSUM (TO rate) as Y-axis so as to understand the learning curve of robotic SADI-S. Results: The operative time of 77 robotic SADI-S was (182.9±37.5) minutes, and the length of postoperative hospital stay was 6 (4-55) days. There was no conversion to laparotomy or death. Seven patients suffered from complications (7/77, 9.1%). Four patients had grade II complications (5.2%), including one with duodeno-ileal anastomotic leakage, one with abdominal bleeding, one with peritoneal effusion and one with delayed gastric emptying; two patients were grade IIIb complications (2.6%) and both of them were diagnosed with gastric leakage; one patient was grade IV complication diagnosed with postoperative respiratory failure (1.3%), and all of them were cured successfully. A total of 51 patients met the textbook outcome standard, and the TO rate was positive and was steadily increasing after the number of surgical cases accumulated to the 46th case. Taking the 46th case as the boundary, all the patients were divided into learning stage group (n=46) and mastery stage group (n=31). There were no significant differences between the two groups in terms of gender, age, weight, body mass index, waist circumference, ASA classification, standard liver volume, operative time and morbidity of postoperative complication (all P>0.05). The percent of abdominal drainage tube in learning stage group was higher than that in mastery stage group (54.3% versus 16.1%, P<0.05). The length of postoperative hospital stay in learning stage group was longer than that in mastery stage group [6 (4-22) d versus 6 (5-55) d, P<0.05)]. Conclusion: The Da Vinci robotic SADI-S is safe and feasible with a learning curve of 46 cases.

Adult , Female , Humans , Male , Middle Aged , Anastomosis, Surgical , Diabetes Mellitus, Type 2/surgery , Gastrectomy/methods , Gastric Bypass/adverse effects , Learning Curve , Obesity/surgery , Obesity, Morbid/surgery , Retrospective Studies , Robotic Surgical Procedures
Rev. colomb. ortop. traumatol ; 34(2): 129-136, 2020. ilus
Article in Spanish | LILACS, COLNAL | ID: biblio-1372386


Introducción El pie diabético infectado es una complicación frecuente de la diabetes y un marcador de deterioro del paciente. Existe escasa información en Colombia sobre características de los pacientes que ingresan a los servicios de urgencias de alta complejidad con esta patología y desenlaces como amputación y perfil microbiológico. Materiales y Métodos Serie de casos de pacientes que ingresaron al servicio de urgencias del Hospital Pablo Tobón Uribe con motivo de consulta principal pie diabético infectado. Se analizaron las historias clínicas de manera retrospectiva y se utilizaron herramientas de estadística descriptiva para la caracterización de la población y de variables relacionadas con diagnóstico, tratamiento y resultados tempranos intrahospitalarios. Resultados Entre enero de 2009 y diciembre de 2013 ingresaron 118 pacientes con 145 úlceras infectadas por pie diabético, el 90% con HbAc>6.5, el 52% con disfunción renal, el 51% con enfermedad arterial periférica. El 57% tenía úlceras grado 3 o mayor en la clasificación de Wagner, la infección fue polimicrobiana en el 63%. El 58% requirió amputación, el 62% de las amputaciones fueron amputaciones menores. La mortalidad fue del 10%, la mortalidad atribuible a infección del pie diabético o complicaciones derivadas de la amputación fue del 1,7%. Discusión Los pacientes con pie diabético que ingresaron a urgencias de un hospital de alta complejidad en Colombia tienen una enfermedad sistémica avanzada, relacionada con disfunción renal y vascular periférica, lesiones locales graves con compromiso óseo y articular avanzado; dada la gravedad de estas condiciones, la prevalencia de amputaciones mayores puede ser superior a la reportada en la literatura. Nivel de Evidencia: IV

Background Infected diabetic foot is a frequent complication of diabetes and a marker of patient deterioration. There is little information in Colombia on the characteristics of patients that enter the highly complex emergency services with this condition and their outcomes, such as amputation and microbiological profile. Materials Case series of patients admitted to the emergency department of Pablo Tobón Uribe Hospital whose main consultation was infected diabetic foot. The medical records were retrospectively analysed and descriptive statistical tools were used to characterise the population, as well as the variables related to diagnosis, treatment, and early in-hospital outcomes. Results Between January 2009 and December 2013, 118 patients with 145 ulcers due to an infected diabetic foot were admitted. The HbA1c was> 6.5 in 90%, and 52% had renal dysfunction, 51% with peripheral arterial disease, and 57% had ulcers grade 3 or higher in the Wagner classification. The infection was polymicrobial in 63%, and 58% required amputation, with 62% of amputations being classed as minor. Mortality was 10%, and mortality attributable to diabetic foot infection or complications derived from amputation was 1.7%. Discussion Patients with diabetic foot admitted to the emergency room of a high complexity hospital in Colombia have an advanced systemic disease, related to renal and peripheral vascular dysfunction, and serious local injuries with advanced bone and joint involvement. Given the severity of these conditions, the prevalence of major amputations may be higher than that reported in the literature. Evidence Level: IV

Humans , Male , Female , Middle Aged , Aged , Surgical Wound Infection/microbiology , Diabetic Foot/surgery , Diabetes Mellitus, Type 2/surgery , Hospitalization , Retrospective Studies , Foot Ulcer/classification , Diabetic Foot/microbiology , Emergency Treatment , Amputation, Surgical
Rev. méd. Chile ; 146(10): 1175-1183, dic. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-978753


Diabetes Mellitus (DM) and obesity are a public health problem in Chile. Bariatric surgery is the most effective treatment alternative to achieve a significant and sustained weight reduction in patients with morbid obesity. The results of controlled clinical trials indicate that, compared to medical treatment, surgery for obese patients with DM2 allows a better control of blood glucose and cardiovascular risk factors, reduces the need for medications and increases the likelihood for remission. Consensus conferences and clinical practice guidelines support bariatric surgery as an option to treat DM2 in Class III Obesity (Body Mass Index (BMI) > 40) regardless of the glycemic control and the complexity of pharmacological treatment and in Class II Obesity (BMI 35-39,9) with inadequate glycemic control despite optimal pharmacological treatment and lifestyle. However, surgical indication for patients with DM2 and BMI between 30-34.9, the most prevalent sub-group, is only suggested. The Chilean Societies of Endocrinology and Diabetes and of Bariatric and Metabolic Surgery decided to generate a consensus regarding the importance of other factors related to DM2 that would allow a better selection of candidates for surgery, particularly when weight does not constitute an indication. Considering the national reality, we also need a statement regarding the selection and characteristics of the surgical procedure as well as the role of the diabetologist in the multidisciplinary team.

Humans , Diabetes Mellitus, Type 2/surgery , Bariatric Surgery/methods , Obesity/surgery , Societies, Medical , Body Mass Index , Chile , Risk Factors , Treatment Outcome , Medical Illustration
Arch. Health Sci. (Online) ; 25(3): 15-17, 21/12/2018.
Article in Portuguese | LILACS | ID: biblio-1046343


Introdução: A obesidade é um grave problema de saúde pública, de difícil manejo. Importante fator de risco para doenças cardiovasculares e metabólicas, a doença interfere significativamente na qualidade de vida e condição de saúde dos indivíduos afetados. Objetivo: Relatar o caso clínico de um paciente com cardiopatia, diabetes mellitus e obesidade, que após insucesso no controle dos níveis glicêmicos foi submetido à gastroplastia. Relato do caso: Paciente de sexo masculino, 56 anos, diabético e coronariopata, submetido à gastroplastia Y de Roux após insucesso com o trata-mento conservador para perda de peso. Observou-se redução significante dos níveis glicêmicos no pós-operatório imediato (89 mg/dL) e após três meses da cirurgia (107 mg/dL), quando comparado ao período pré-cirurgia (215mg/dL) Conclusão: A Cirurgia Bariátrica mostra-se como importante alternativa de tratamento para obesidade, principalmente para aqueles pacientes com comorbidades associadas, como o diabetes mellitus tipo 2, os quais não apresentam boa resposta ao tratamento conservador

Introduction: Obesity is a serious public health problem. Obesity management is very difficult to deal with. This is an important risk factor for cardiovascular and metabolic diseases. Obesity significantly interferes with the individuals' quality of life and health condition. Objective: Report the clinical case of a patient with heart disease, diabetes mellitus, and obesity that have failed to control glycemic levels and underwent a gastroplasty. Case report: The patient is a 56-year-old male, diabetic with coronary artery disease, submitted to Roux-en-Y gastroplasty after failure of conservative treatment for weight loss. We observed a significant reduction of glycemic levels in the immediate postoperative period (89 mg/dL) and after three months of surgery (107 mg/dL), when compared to the preoperative period (215 mg/dL). Conclusion: Bariatric surgery may be an important alternative treatment to obesity, especially for those patients with associated comorbidities, such as type 2 diabetes mellitus, who do not present a good response to conservative treatment

Humans , Middle Aged , Therapeutics/methods , Diabetes Mellitus, Type 2/surgery , Bariatric Surgery , Obesity/surgery
ABCD (São Paulo, Impr.) ; 30(4): 283-286, Oct.-Dec. 2017.
Article in English | LILACS | ID: biblio-885751


ABSTRACT Background : Currently, bariatric surgery has promoted weight loss and improved glycemic control in obese patients through different techniques, including vertical sleeve gastrectomy. Aim : Present and update the different vertical sleeve gastrectomy ways of action, both in the treatment of obesity and diabetes, approaching its potential effect on gastrointestinal physiology, as well as the benefits achieved by this manipulation. Methods : Pubmed database search was used crossing the headings: obesity, type 2 diabetes and sleeve gastrectomy. Results : Published data have shown that short-term weight loss tends to be higher in patients undergoing vertical sleeve gastrectomy compared to Roux-en-Y gastric bypass. In relation to glycemic control, the procedure demonstrated remission of diabetes in up to 60% after one year of surgery. After three years, however, differences in remission rate between surgical and clinical group was not observed, questioning the durability of the technical in a long-term. Conclusion : Despite showing good results, both in the weight loss and co-morbidities, conflicting results reinforce the need for more studies to prove the efficiency of the vertical sleeve gastrectomy as well as to understand its action about the molecular mechanisms involved in the disease.

RESUMO Racional : Nos últimos anos a cirurgia bariátrica vem promovendo a perda de peso e melhora do controle glicêmico em pacientes obesos por meio de diversas técnicas, entre elas a gastrectomia vertical. Objetivo : Apresentar e atualizar as diferentes formas da ação da gastrectomia vertical, tanto no tratamento da obesidade quanto no diabete, abordando seu potencial efeito na fisiologia gastrointestinal, assim como os benefícios obtidos por meio desta manipulação. Método : Foi realizada revisão de literatura utilizando artigos selecionados na base de dados Pubmed, por meio dos descritores: obesity, type 2 diabetes e sleeve gastrectomy. Resultados : Dados publicados demonstraram que a perda de peso em curto prazo tende a ser maior nos pacientes submetidos à gastrectomia vertical quando comparada ao desvio gástrico em Y-de-Roux. Em relação ao controle glicêmico, a técnica apresentou remissão da taxa de diabete em até 60% após um ano. Após três anos, entretanto, diferença na taxa de remissão entre o grupo cirúrgico e clínico não foram evidenciadas, questionando a durabilidade da técnica em longo prazo. Conclusão : Apesar de apresentar bons resultados no tratamento da obesidade e co-morbidades, resultados conflitantes reforçam a necessidade de mais estudos para demonstrar a eficiência da gastrectomia vertical, assim como para compreender sua ação sobre os mecanismos moleculares envolvidos na doença.

Humans , Gastric Bypass , Gastroplasty , Diabetes Mellitus, Type 2/surgery , Obesity/surgery , Diabetes Mellitus, Type 2/complications , Obesity/complications
Rev. Col. Bras. Cir ; 43(3): 149-153, May.-June 2016. tab, graf
Article in English | LILACS | ID: lil-792816


ABSTRACT Objective: to evaluate the effectiveness of Roux-en-Y gastric bypass in improving the glycemic profile of obese patients with type 2 Diabetes Mellitus (DM2) after 18 months of follow-up. Methods: four hundred sixty-eight pacients with DM2 and BMI ≥35 were submitted to Roux-en-Y gastric bypass, from 1998 to 2010. All patients were submitted to glycemic control analysis in the 3rd, 6th, 9th, 12th and 18th postoperative months. We considered: type 2 diabetic patients, the ones with fasting glucose ≥126mg/dl and HbA1C ≥6.5 in two dosages; high risk patients for diabetes, those who presented fasting glucose ≥ 100 to 125 mg/dl and HbA1C between 5.7%-6.4%; and normal patients, those presenting glucose <100mg/dl and HbA1C <5.7%. Such diagnostic criteria were based on the official position of Sociedade Brasileira de Diabetes, published in July, 2011. Results: The remission of DM2 was seen in 410 (87.6%) out of 468 patients 18 months after the surgery, that being a meaningful difference, with p<0.001. Fourty-eight (10.3%) patients sustained criteria for the disease and ten (2.1%) continued at high risk for DM2. Conclusions: Roux-en-Y gastric bypass was effective in the promotion and maintaince of long-term glycemic control. There are evidences showing that the remission of DM2 is not only related to weight loss and that other enteroinsular axis mechanisms must be involved.

RESUMO Objetivo: avaliar a eficácia da gastroplastia com derivação em Y-de-Roux, em pacientes obesos e portadores de Diabetes Mellitus tipo 2 (DM2), na melhoria do perfil glicêmico após 18 meses de seguimento. Métodos: foram submetidos à derivação gástrica em Y-de-Roux 468 pacientes com IMC ≥35 e portadores de DM2, no período de 1998 a 2010. Todos os pacientes tiveram a análise do controle glicêmico realizadas no terceiro, sexto, nono, 12o e 18o meses de pós-operatório. Os critérios diagnósticos de diabetes foram baseados no Posicionamento Oficial da Sociedade Brasileira de Diabetes, publicado em julho de 2011. Resultados: observou-se a remissão do DM2 em 410 pacientes (87,6%) após 18 meses da cirurgia, sendo essa diferença significativa com p-valor <0,001. A doença se manteve inalterada em 48 pacientes (10,3%), e dez pacientes (2,1%) permaneceram com o risco aumentado para DM2. Conclusão: a gastroplastia com derivação em Y-de-Roux foi efetiva na promoção e manutenção do controle glicêmico em longo prazo.

Humans , Male , Female , Adolescent , Adult , Aged , Young Adult , Gastric Bypass , Diabetes Mellitus, Type 2/surgery , Time Factors , Blood Glucose/analysis , Obesity, Morbid , Obesity, Morbid/complications , Obesity, Morbid/blood , Remission Induction , Treatment Outcome , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/blood , Middle Aged
ABCD (São Paulo, Impr.) ; 29(supl.1): 102-106, 2016. graf
Article in English | LILACS | ID: lil-795039


ABSTRACT Introduction Even considering the advance of the medical treatment in the last 20 years with new and more effective drugs, the outcomes are still disappointing as the control of obesity and type 2 Diabetes Mellitus (T2DM) with a large number of patients under the medical treatment still not reaching the desired outcomes. Objective: To present a Metabolic Risk Score to better guide the surgical indication for T2DM patients with body mass index (BMI) where surgery for obesity is still controversial. Method: Research was conducted in Pubmed, Medline, Pubmed Central, Scielo and Lilacs between 2003-2015 correlating headings: metabolic surgery, obesity and type 2 diabetes mellitus. In addition, representatives of the societies involved, as an expert panel, issued opinions. Results: Forty-five related articles were analyzed by evidence-based medicine criteria. Grouped opinions sought to answer the following questions: Why metabolic and not bariatric surgery?; Mechanisms involved in glycemic control; BMI as a single criterion for surgical indication for uncontrolled T2DM; Results of metabolic surgery studies in BMI<35 kg/m2; Safety of metabolic surgery in patients with BMI<35 kg/m2; Long-term effects of surgery in patients with baseline BMI<35 kg/m2 and Proposal for a Metabolic Risk Score. Conclusion: Metabolic surgery has well-defined mechanisms of action both in experimental and human studies. Gastrointestinal interventions in T2DM patients with IMC≤35 kg/m2 has similar safety and efficacy when compared to groups with greater BMIs, leading to the improvement of diabetes in a superior manner than clinical treatment and lifestyle changes, in part through weight loss independent mechanisms . There is no correlation between baseline BMI and weight loss in the long term with the success rate after any surgical treatment. Gastrointestinal surgery treatment may be an option for patients with T2DM without adequate clinical control, with a BMI between 30 and 35, after thorough evaluation following the parameters detailed in Metabolic Risk Score defined by the surgical societies. Roux-en-Y gastric bypass (RYGB), because of its well known safety and efficacy and longer follow-up studies, is the main surgical technique indicated for patients eligible for surgery through the Metabolic Risk Score. The vertical sleeve gastrectomy may be considered if there is an absolute contraindication for the RYGB. T2DM patients should be evaluated by the multiprofessional team that will assess surgical eligibility, preoperative work up, follow up and long term monitoring for micro and macrovascular complications.

RESUMO Introdução: Mesmo considerando o avanço do tratamento clínico ocorrido nos últimos 20 anos, com novos e mais eficientes medicamentos, os dados ainda são desanimadores quanto ao controle da obesidade e da diabete melito tipo 2 (DMT2),com grande parcela de doentes em tratamento clínico ficando fora da meta desejada de controle. Objetivo: Apresentar proposta de Escore de Risco Metabólico para melhor orientar a indicação cirúrgica do diabete em pacientes com índice de massa corpórea (IMC) mais baixo nos quais o uso de procedimento cirúrgico para obesidade ainda é controverso. Método: Foi realizada pesquisa nas bases de dados Pubmed, Medline, Pubmed Central, Scielo e Lilacs entre 2003-2015 correlacionando os descritores:cirurgia metabólica, obesidade e diabete melito tipo 2. Adicionalmente, representantes das sociedades envolvidas emitiram opiniões em pontos nos quais não existia na literatura trabalhos com graus de evidência elevados. Resultados: Foram encontrados 45 artigos relacionados que foram analisados pelos critérios da medicina baseada em evidências. As opiniões agrupadas procuraram responder as seguintes questões: Porque cirurgia metabólica e não bariátrica?; Mecanismos envolvidos no controle glicêmico; IMC como critério isolado de indicação cirúrgica para o DMT2 não controlado; Resultados de estudos de cirurgia metabólica em IMC<35 kg/m2; Segurança da cirurgia metabólica em pacientes com IMC<35 kg/m2; Efeitos em longo prazo da cirurgia em pacientes com IMC inicial <35 kg/m2; Proposta de Escore de Risco Metabólico. Conclusão: A cirurgia metabólica tem mecanismos de ação bem definidos tanto em estudos experimentais quanto em seres humanos. As intervenções gastrointestinais em diabéticos com IMC≤35 kg/m2 possuem segurança e eficácia semelhantes aos grupos com IMCs maiores, levando a melhora do diabete de forma superior aos tratamentos clínicos e mudanças de estilo de vida, em parte através de mecanismos independentes da perda ponderal. Não há correlação entre o IMC inicial e perda ponderal em longo prazo com os índices de sucesso do tratamento cirúrgico. O tratamento cirúrgico é opção para os pacientes portadores de DMT2 sem adequado controle clínico, com IMC entre 30 e 35, após minuciosa avaliação seguindo os parâmetros dispostos no Escore de Risco Metabólico aqui proposto. DGYR é a técnica indicada para os pacientes selecionados no Escore, existindo a possibilidade de indicação da gastrectomia vertical para os casos em que exista contraindicação para ela. O paciente deve ser avaliado por equipe multiprofissional envolvida na indicação, preparo e acompanhamento após as operações e acompanhados com monitorização de complicações micro e macrovasculares.

Humans , Diabetes Mellitus, Type 2/surgery , Diabetes Mellitus, Type 2/complications , Bariatric Surgery , Obesity/surgery , Obesity/complications , Severity of Illness Index
J. bras. nefrol ; 37(3): 399-409, July-Sept. 2015. tab, ilus
Article in Portuguese | LILACS | ID: lil-760445


ResumoIntrodução:O diabetes mellitus tipo 2 (DM2) é caracterizado por uma desregulação metabólica, originando complicações microvasculares, mais especificamente a retinopatia, nefropatia e a neuropatia. A prevenção e tratamento das complicações são alvo da farmacoterapia, porém, evidências demonstram que a cirurgia bariátrica/metabólica é superior ao melhor tratamento farmacológico, pois apresenta melhor controle da glicemia, hipertensão e dislipidemias.Métodos:Por meio de pesquisa no PubMed, são discutidas as recentes publicações que evidenciam o efeito positivo das intervenções cirúrgicas sobre as complicações microvasculares, como melhora da microalbuminúria e mesmo preservação de função renal.Discussão:Existem evidências de benefício das operações bariátricas/metabólicas sobre a nefropatia diabética. Os dados sobre retinopatia são ainda ambivalentes. Na literatura, há uma diferença significativa no benefício da cirurgia em neuropatia.Conclusão:Apesar de resultados surpreendentes e positivos, para que se estabeleça definitivamente o papel da cirurgia bariátrica/metabólica nas complicações micovasculares do DM2, há a necessidade de novos estudos randomizados controlados e prospectivos.

AbstractIntroduction:Metabolic dysregulation is the defining characteristic of type 2 diabetes mellitus (T2DM) and may lead to microvascular complications, specifically retinopathy, nephropathy and neuropathy. Medical treatment and lifestyle interventions targeting risk factors for microvascular complications can yield therapeutic gains, particularly retinopathy and nephropathy. Bariatric/metabolic surgery is superior to the best medical treatment in several randomized controlled trials. Consequently, evidence of the effect of bariatric/metabolic surgery on microvascular complications is now emerging in the literature.Methods:A search of the recent published evidence base on the effects of bariatric/metabolic surgery on microvascular complications reveals further evidence that supports the efficacy of surgery in preventing the incidence and progression of albuminuria and preserving renal functional decline.Discussion:Data on retinopathy are ambivalent representing the potential in some cases for an influence of reactive hypoglycaemia over the retina but the majority of data emphasize that the metabolic control can halt the progression of the eye disease. A significant gap in the literature remains in relation to the effects of surgery on diabetic neuropathy, although some information sheds a light on the benefits secondary to the surgical metabolic control.Conclusion:Overall, although data so far is exciting, there is a pressing need for prospective randomized controlled trials examining long-term microvascular outcomes following bariatric/metabolic surgery in patients with T2DM.

Humans , Diabetes Mellitus, Type 2/surgery , Diabetes Mellitus, Type 2/complications , Diabetic Angiopathies/surgery , Diabetic Angiopathies/etiology , Bariatric Surgery , Microvessels , Prospective Studies , Retrospective Studies , Treatment Outcome
Rev. Hosp. Clin. Univ. Chile ; 24(1): 25-31, 2013. ilus
Article in Spanish | LILACS | ID: biblio-999089


Type 2 diabetes mellitus (T2D) is a health problem worldwide, and is associated with serious health consequences. The development of T2D has a strong association with obesity, sedentary lifestyle, genetic factors and other associations of diabetes. Faced with this problem, bariatric surgery has evolved as the treatment that produced a greater decrease in body weight in the long term, unlike the medical treatment. Moreover, it is postulated that bariatric surgery currently may have a beneficial effect in improving the treatment or even diabetes remission in obese patients. (AU)

Humans , Male , Female , Diabetes Mellitus, Type 2/surgery , Bariatric Surgery/methods , Diabetes Mellitus, Type 2/etiology , Diabetes Mellitus, Type 2/physiopathology , Obesity/surgery
Article in English | IMSEAR | ID: sea-85400


We report our results with live related renal transplantation in 43 diabetics, most of whom were non-insulin dependent, with end stage renal disease. The overall one year patient survival was 72.1% and graft survival was 65.1%. The use of Cyclosporine was associated with a significant improvement in the one year patient and graft survival (92.3% and 84.6% respectively). The most important cause of mortality was infection. Live related renal transplantation with Cyclosporine as immunosuppression is advisable for the uremic diabetic.

Actuarial Analysis , Adult , Diabetes Mellitus, Type 1/surgery , Diabetes Mellitus, Type 2/surgery , Diabetic Nephropathies/surgery , Female , Follow-Up Studies , Humans , Kidney Failure, Chronic/surgery , Kidney Function Tests , Kidney Transplantation/physiology , Male , Middle Aged , Postoperative Complications/diagnosis , Tissue Survival/physiology